196 related articles for article (PubMed ID: 35727604)
1. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
[TBL] [Abstract][Full Text] [Related]
2. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract][Full Text] [Related]
3. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
[TBL] [Abstract][Full Text] [Related]
4. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
5. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
[TBL] [Abstract][Full Text] [Related]
6. Belzutifan: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States.
Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
Orphanet J Rare Dis; 2024 Feb; 19(1):73. PubMed ID: 38365728
[TBL] [Abstract][Full Text] [Related]
8. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
9. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
10. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
11. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
[TBL] [Abstract][Full Text] [Related]
13. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.
Lonser RR; Butman JA; Huntoon K; Asthagiri AR; Wu T; Bakhtian KD; Chew EY; Zhuang Z; Linehan WM; Oldfield EH
J Neurosurg; 2014 May; 120(5):1055-62. PubMed ID: 24579662
[TBL] [Abstract][Full Text] [Related]
14. Exceptional and Sustained Response to Belzutifan in Von Hippel-Lindau Disease-Associated Central Nervous System Hemangioblastoma.
Thalji M; Vadlapatla V; Avgeropoulos NG; Ramakrishna N; Baidas S
Cureus; 2024 Jan; 16(1):e52979. PubMed ID: 38406059
[TBL] [Abstract][Full Text] [Related]
15. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.
Dhawan A; Peereboom DM; Stevens GH
CNS Oncol; 2022 Jul; 11(3):CNS91. PubMed ID: 35819008
[TBL] [Abstract][Full Text] [Related]
16. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.
Heo SJ; Lee CK; Hahn KY; Kim G; Hur H; Choi SH; Han KS; Cho A; Jung M
Cancer Res Treat; 2016 Jan; 48(1):409-14. PubMed ID: 25715769
[TBL] [Abstract][Full Text] [Related]
17. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
[TBL] [Abstract][Full Text] [Related]
18. Metastases to hemangioblastomas in von Hippel-Lindau disease.
Jarrell ST; Vortmeyer AO; Linehan WM; Oldfield EH; Lonser RR
J Neurosurg; 2006 Aug; 105(2):256-63. PubMed ID: 17219831
[TBL] [Abstract][Full Text] [Related]
19. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
Shepherd STC; Drake WM; Turajlic S
Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
[TBL] [Abstract][Full Text] [Related]
20. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]